“India is already one of the world’s leading pharmaceutical manufacturers. Its generics industry supplies a significant share of global medicine needs. Its medical devices sector, while younger, is growing rapidly. What is less often acknowledged is how well-positioned this base is to move up the value chain into smarter, more integrated healthcare products.” Gunjan Ramteke, Partner Development Manager at Amazon Web Services (AWS) and an Independent Researcher
Most conversations about healthcare transformation begin with software, AI models, or clinical breakthroughs. Rarely do they begin with the factory floor. That is a mistake, and one that India’s manufacturing sector can no longer afford to make.
A convergence is underway across technology, pharma, and healthcare. But beneath the headlines about AI diagnostics and precision medicine lies a more fundamental shift: the physical infrastructure of healthcare, including devices, diagnostics, drug manufacturing, and connected health hardware, is becoming as strategically important as the algorithms that run on top of it. India is better positioned than most to lead this shift. The question is whether its ecosystem recognizes the opportunity before others do.
The convergence is real, but manufacturing is its foundation
For years, technology, pharma, and healthcare delivery operated in separate lanes. Pharma companies discovered and manufactured drugs. Hospitals diagnosed and treated patients. Technology companies have built systems to improve efficiency across both.
That model is breaking down. A medicine today is rarely just a product. It is increasingly part of a broader care journey that includes diagnostics, patient monitoring, digital adherence tools, and outcome tracking. A hospital is no longer only a site of care. It is a source of clinical data, real-world evidence, and operational insight. Technology connects these layers, but none of it functions without reliable, high-quality physical infrastructure.
This is where manufacturing enters the picture, not as a supporting function but as a strategic enabler. Smart diagnostic devices, AI-enabled imaging systems, connected monitoring equipment, and digital pathology platforms all sit at the intersection of manufacturing, healthcare, and technology. The organizations that build these products well, at scale, with precision and compliance, are the ones that will define the next phase of healthcare delivery.
India’s manufacturing base is underestimated in this context
India is already one of the world’s leading pharmaceutical manufacturers. Its generics industry supplies a significant share of global medicine needs. Its medical devices sector, while younger, is growing rapidly. What is less often acknowledged is how well-positioned this base is to move up the value chain into smarter, more integrated healthcare products.
Having worked across AI, cloud platforms, and biotech, what I observe consistently is that the bottleneck in healthcare innovation is rarely the algorithm. It is the data, the device, and the manufacturing system that generates reliable inputs in the first place. An AI model for diagnostic imaging is only as good as the imaging hardware it depends on. India has the engineering talent and manufacturing depth to own more of this stack than it currently does.
The gap is not capability. It is coordination. Pharma manufacturers, device makers, software companies, and healthcare providers in India are still largely working in parallel rather than in concert. Closing that gap is not just an industry problem. It is a policy problem. Industrial strategy, procurement frameworks, and R&D investment priorities all shape whether convergence happens by design or by accident. The countries that will lead in healthcare manufacturing over the next decade are the ones making deliberate choices about this today.
Research and R&D as the missing link
No manufacturing transformation sustains itself without a strong research foundation feeding into it. India has world-class researchers working across genomics, biomedical engineering, computational biology, and materials science. The gap is in translation. Building stronger industry-academia linkages, supporting applied research with commercial intent, and creating infrastructure where R&D outputs connect directly to manufacturing pipelines would accelerate India’s position in healthcare innovation far more than technology investment alone.
What this means in practice
The practical implication for India’s manufacturing sector is a shift in how product categories are defined. A glucose monitor is no longer just a hardware product. It is a data-generating endpoint in a diabetes management platform. A diagnostic reagent kit is not just a consumable. It is a component in a decentralized testing ecosystem. An imaging system is not just capital equipment. It is a node in a clinical AI workflow.
Manufacturers that continue to think about their products in isolation will compete on price. Those that understand where their products sit in a larger clinical and data ecosystem will compete on value, and on much better terms. This does not require every manufacturer to become a software company. It requires a sharper understanding of clinical workflows, data interoperability standards, and the regulatory requirements that apply when hardware intersects with AI-driven decision-making.
The governance dimension
Convergence also brings complexity. Healthcare data is sensitive. AI systems in clinical environments must be explainable and governed responsibly. Manufacturers feeding into healthcare applications face higher regulatory scrutiny than traditional industrial production.
India’s frameworks in medical devices and health technology are still maturing. Manufacturers that invest early in quality systems, data governance, and regulatory readiness will use compliance as a competitive differentiator in export markets rather than a barrier. For policymakers, building clear and forward-looking standards in this space is not a bureaucratic exercise. It is an economic one.
The window is open, not indefinitely
Other manufacturing ecosystems, particularly in Southeast Asia and parts of Europe, are moving quickly to position themselves as integrated healthcare manufacturing hubs. India has structural advantages: pharmaceutical depth, engineering talent, domestic healthcare demand, and a growing digital infrastructure. These are real but not permanent.
The next phase of healthcare transformation will be built as much in factories and fabrication facilities as it will in research labs and data centres. India’s manufacturing sector has the foundation. Whether it becomes the backbone of a new global healthcare supply chain depends on decisions being made right now, by industry leaders, researchers, and policymakers working from the same strategic playbook.
The author is Gunjan Ramteke, Partner Development Manager at Amazon Web Services (AWS) and an Independent Researcher
